21 C.F.R. § 800.20
(a) Purpose. The prevalence of human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS), and its risk of transmission in the health care context, have caused the Food and Drug Administration (FDA) to look more closely at the quality control of barrier devices, such as surgeons' gloves and patient examination gloves (collectively known as medical gloves) to reduce the risk of transmission of HIV and other blood-borne infectious diseases. The Centers for Disease Control (CDC) recommend that health care workers wear medical gloves to reduce the risk of transmission of HIV and other blood-borne infectious deseases. The CDC recommends that health care workers wear medical gloves when touching blood or other body fluids, mucous membranes, or nonintact skin of all patients; when handling items or surfaces soiled with blood or other body fluids; and when performing venipuncture and other vascular access procedures. Among other things, CDC's recommendation that health care providers wear medical gloves demonstrates the proposition that devices labeled as medical gloves purport to be and are represented to be effective barriers against the transmission of blood- and fluid-borne pathogens. Therefore, FDA, through this regulation, is defining adulteration for patient examination and surgeons' gloves as a means of assuring safe and effective devices.
(b)
(1) General test method. For the purposes of this part, FDA's analysis of gloves for leaks and visual defects will be conducted by a visual examination and by a water leak test method, using 1,000 milliliters (ml) of water.
(2) Leak test materials. FDA considers the following to be the minimum materials required for this test :
(3) Visual defects and leak test procedures. Examine the sample and identify code/lot number, size, and brand as appropriate. Continue the visual examination using the following procedures:
(ii) Leak test set-up.
(iii) Leak test examination. Immediately after adding the water, examine the glove for water leaks. Do not squeeze the glove; use only minimum manipulation to spread the fingers to check for leaks. Water drops may be blotted to confirm leaking.
(c) Sampling, inspection, acceptance, and adulteration. In performing the test for leaks and other visual defects described in paragraph (b) of this section, FDA will collect and inspect samples of medical gloves, and determine when the gloves are acceptable as set out in paragraphs (c)(1) through (c)(3) of this section.
(3) Adulteration levels and accept/reject criteria. FDA considers a lot of medical gloves to be adulterated when the number of defective gloves found in the tested sample meets or exceeds the applicable rejection number at the 1.5 AQL for surgeons' gloves or the 2.5 AQL for patient examination gloves. These acceptance and rejection numbers are identified in the tables following paragraph (c)(3) of this section as follows:
| Lot Size | Sample | Sample Size | Number Examined | Number Defective | |
|---|---|---|---|---|---|
| Accept | Reject | ||||
| 8 to 90 | Single sample | 8 | 0 | 1 | |
| 91 to 280 | Single sample | 32 | 1 | 2 | |
| 281 to 500 | Single sample | 50 | 2 | 3 | |
| 501 to 1,200 | Single sample | 80 | 3 | 4 | |
| 1,201 to 3,200 | First | 32 | 32 | — | 4 |
| Second | 32 | 64 | 1 | 5 | |
| Third | 32 | 96 | 2 | 6 | |
| Fourth | 32 | 128 | 3 | 7 | |
| Fifth | 32 | 160 | 5 | 8 | |
| Sixth | 32 | 192 | 7 | 9 | |
| Seventh | 32 | 224 | 9 | 10 | |
| 3,201 to 10,000 | First | 50 | 50 | 0 | 4 |
| Second | 50 | 100 | 1 | 6 | |
| Third | 50 | 150 | 3 | 8 | |
| Fourth | 50 | 200 | 5 | 10 | |
| Fifth | 50 | 250 | 7 | 11 | |
| Sixth | 50 | 300 | 10 | 12 | |
| Seventh | 50 | 350 | 13 | 14 | |
| 10,001 to 35,000 | First | 80 | 80 | 0 | 5 |
| Second | 80 | 160 | 3 | 8 | |
| Third | 80 | 240 | 6 | 10 | |
| Fourth | 80 | 320 | 8 | 13 | |
| Fifth | 80 | 400 | 11 | 15 | |
| Sixth | 80 | 480 | 14 | 17 | |
| Seventh | 80 | 560 | 18 | 19 | |
| 35,000 | First | 125 | 125 | 1 | 7 |
| Second | 125 | 250 | 4 | 10 | |
| Third | 125 | 375 | 8 | 13 | |
| Fourth | 125 | 500 | 12 | 17 | |
| Fifth | 125 | 625 | 17 | 20 | |
| Sixth | 125 | 750 | 21 | 23 | |
| Seventh | 125 | 875 | 25 | 26 |
| Lot Size | Sample | Sample Size | Number Examined | Number Defective | |
|---|---|---|---|---|---|
| Accept | Reject | ||||
| 5 to 50 | Single sample | 5 | 0 | 1 | |
| 51 to 150 | Single sample | 20 | 1 | 2 | |
| 151 to 280 | Single sample | 32 | 2 | 3 | |
| 281 to 500 | Single sample | 50 | 3 | 4 | |
| 501 to 1,200 | Single sample | 80 | 5 | 6 | |
| 1,201 to 3,200 | First | 32 | 32 | 0 | 4 |
| Second | 32 | 64 | 1 | 6 | |
| Third | 32 | 96 | 3 | 8 | |
| Fourth | 32 | 128 | 5 | 10 | |
| Fifth | 32 | 160 | 7 | 11 | |
| Sixth | 32 | 192 | 10 | 12 | |
| Seventh | 32 | 224 | 13 | 14 | |
| 3,201 to 10,000 | First | 50 | 50 | 0 | 5 |
| Second | 50 | 100 | 3 | 8 | |
| Third | 50 | 150 | 6 | 10 | |
| Fourth | 50 | 200 | 8 | 13 | |
| Fifth | 50 | 250 | 11 | 15 | |
| Sixth | 50 | 300 | 14 | 17 | |
| Seventh | 50 | 350 | 18 | 19 | |
| 10,001 to 35,000 | First | 80 | 80 | 1 | 7 |
| Second | 80 | 160 | 4 | 10 | |
| Third | 80 | 240 | 8 | 13 | |
| Fourth | 80 | 320 | 12 | 17 | |
| Fifth | 80 | 400 | 17 | 20 | |
| Sixth | 80 | 480 | 21 | 23 | |
| Seventh | 80 | 560 | 25 | 26 | |
| 35,000 and above | First | 125 | 125 | 2 | 9 |
| Second | 125 | 250 | 7 | 14 | |
| Third | 125 | 375 | 13 | 19 | |
| Fourth | 125 | 500 | 19 | 25 | |
| Fifth | 125 | 625 | 25 | 29 | |
| Sixth | 125 | 750 | 31 | 33 | |
| Seventh | 125 | 875 | 37 | 38 |
(d) Compliance. Lots of gloves that are sampled, tested, and rejected using procedures in paragraphs (b) and (c) of this section, are considered adulterated within the meaning of section 501(c) of the act.
(2) Reconditioning. FDA may authorize the owner of the product, or the owner's representative, to attempt to recondition, i.e., bring into compliance with the act, a lot or part of a lot of foreign gloves detained at importation, or a lot or part of a lot of seized domestic gloves.
(i) Modified sampling, inspection, and acceptance. If FDA authorizes reconditioning of a lot or portion of a lot of adulterated gloves, testing to confirm that the reconditioned gloves meet AQLs must be performed by an independent testing facility. The following tightened sampling plan must be followed, as described in ISO 2859 “Sampling Procedures for Inspection by Attributes:”
(ii) Adulteration levels and acceptance criteria for reconditioned gloves.
(B) FDA considers a reconditioned lot of medical gloves to be adulterated within the meaning of section 501(c) of the act when the number of defective gloves found in the tested sample meets or exceeds the applicable rejection number in the tables following paragraph (d)(2)(ii)(B) of this section:
| Lot Size | Sample | Sample Size | Number Defective | |
|---|---|---|---|---|
| Accept | Reject | |||
| 13 to 90 | Single sample | 13 | 0 | 1 |
| 91 to 500 | Single sample | 50 | 1 | 2 |
| 501 to 1,200 | Single sample | 80 | 2 | 3 |
| 1,201 to 3,200 | Single sample | 125 | 3 | 4 |
| 3,201 to 10,000 | Single sample | 200 | 5 | 6 |
| 10,001 to 35,000 | Single sample | 315 | 8 | 9 |
| 35,000 and above | Single sample | 500 | 12 | 13 |
| Lot Size | Sample | Sample Size | Number Defective | |
|---|---|---|---|---|
| Accept | Reject | |||
| 8 to 50 | Single sample | 8 | 0 | 1 |
| 51 to 280 | Single sample | 32 | 1 | 2 |
| 281 to 500 | Single sample | 50 | 2 | 3 |
| 501 to 1,200 | Single sample | 80 | 3 | 4 |
| 1,201 to 3,200 | Single sample | 125 | 5 | 6 |
| 3,201 to 10,000 | Single sample | 200 | 8 | 9 |
| 10,001 to 35,000 | Single sample | 315 | 12 | 13 |
| 35,000 and above | Single sample | 500 | 18 | 19 |
[55 FR 51256, Dec. 12, 1990, as amended at 71 FR 75876, Dec. 19, 2006]